Publications by authors named "L V Rizzo"

In this work, the effect of the electro-assisted Fenton (EAF) process on the bacterial community of a moving bed biofilm reactor (MBBR) for olive mill wastewater (OMW) co-treatment with urban wastewater (UWW) was investigated. According to metagenomic analysis, pre-treatment by EAF, while removing total phenols (TPHs) up to 84 % ± 3 % and improving biodegradability of OMW from 0.38 to 0.

View Article and Find Full Text PDF

3D printing has become essential to many fields for its low-cost production and rapid prototyping abilities. As 3D printing becomes an alternative manufacturing tool, developing methods to non-destructively evaluate defects for quality control is essential. This study integrates the non-destructive terahertz (THz) analysis methods of terahertz time-domain spectroscopy (THz-TDS) and terahertz computed tomography (THz CT) to image and assess 3D printed resin structures for defects.

View Article and Find Full Text PDF

Objective: Air pollution emission associated with wildfires is a global concern, contributing to air quality deterioration and severely impacting public health. This narrative review aims to provide an overview of wildfire smoke (WFS) characteristics and associated impacts on adults' and children's health.

Data Source: Literature review based on a bibliographic survey in PubMed (National Library of Medicine, United States), SciELO (Scientific Electronic Library Online), and Google Scholar databases.

View Article and Find Full Text PDF

Spinal muscular atrophy is a rare hereditary neurodegenerative disease characterized by progressive motor neuron loss. The most common form of SMA is linked to 5q (5q-SMA) and is classified into subtypes according to the age of onset and maximum motor function achieved. The severity ranges from progressive infantile paralysis and premature death (type 1) to limited motor neuron loss in adults (type 4).

View Article and Find Full Text PDF

Objective: Tofacitinib, an oral Janus kinase inhibitor, has been tested against a placebo in 289 patients with COVID-19 pneumonia. We analyzed the data from the tofacitinib- and placebo-treated patient cohorts to evaluate the laboratory profiles between baseline and day 7.

Methods: We performed post hoc analyses on the following laboratory tests over time during the first 7 days after randomization: hemoglobin, leukocytes, neutrophils, lymphocytes, platelets, alanine aminotransferase, and aspartate aminotransferase.

View Article and Find Full Text PDF